BIOCON LIMITED

INTRODUCTION

Biocon Limited is a biopharmaceutical

company from India. This company has
brought bio-revolution in India. The
founder of this company was Kiran
Mazumdar Shaw. This company evolved
with time from the field of enzyme
manufacturing to bio-pharmaceuticals.
Biocon Ltd was established in the year
1978. It was a joint venture of Biocon India
with Ireland. In the year 1998, Biocon India
took over Unilever’s part of the company.
Biocon Limited produces generic active
ingredients and sells them in developed
European market. Current value of this
company is 22.40 billion INR.

REPORT TITLE PAGE 2

 SHAREHOLDING PATTERN

Shareholding pattern shows how the total number of shares equity

outstanding in the company is divided between various owners
(individuals and institutions). It shows how the ownership is split
among the entities that make up its owners.
Biocon Limited is not a family owned company; it has a separate
entity.
The Shareholding Pattern page of Biocon Ltd. presents the Promoter's
holding, FII's holding, DII's Holding, and Share holding by general
public.

Major Shareholders

Kiran Mazumdar Shaw, the Ravi Rasendra Mazumdar is

CEO and founder, has the one of the promoters with
highest shares, which consist of 0.38% stake.
475,725,384 numbers of shares,
which makes them 39.64%
stake of the company.

Glentec International is also

one of the major shareholders
consisting of 237,211,164
numbers of shares which leads
to 19.77% stake.

REPORT TITLE PAGE 3

 MANAGEMENT OF THE COMPANY

Kiran Mazumdar Shaw

Executive Chairperson, Biocon Limited

Ms. Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, is a pioneering biotech

entrepreneur, a healthcare visionary, a global influencer, and a passionate philanthropist. The impact
she has made as a leading woman in science has made her a role model in India. She is committed to
equity in healthcare through access and affordability as she pursues a path of making a difference to
billions of lives globally.

Mr. Siddharth Mittal

Managing Director & CEO

Mr. Siddharth Mittal is the Managing Director & CEO of Biocon Limited. He had joined Biocon in
May 2013 and served as President - Finance & Chief Financial Officer between August 2014 &
November 2019.He has over 20 years of global and diversified experience in the field of strategic
finance and accounting, mergers and acquisitions, taxation and general management. Mr. Mittal has
a Bachelor of Commerce (B. Com) degree from the Symbiosis College of Arts and Commerce, Pune.
He is a Chartered Accountant from the Institute of Chartered Accountants of India, New Delhi and a
Certified Public Accountant from Colorado, USA.

Dr. Christiane Hamacher

Chief Executive Officer, Biocon Biologics India Limited

Dr Christiane Hamacher joined as Chief Executive officer (CEO) of Biocon Biologics India Ltd in
March 2019. Dr Hamacher has over 20 years of leadership experience in both strategic and
operational roles across the value chain in global pharma, spanning Asia, Europe and the U.S. She
has been with Roche, Basel, Switzerland since 2007 and prior to that spent 10 years at Schering AG,
Berlin, Germany. She holds a Ph.D. in Molecular Biology (Oncology) from the University Clinic
Bergmannsheil / University of Bochum, Germany. She also studied Economics at the University of
Hagen, Germany.

REPORT TITLE PAGE 4

 SWOT ANALYSIS
OF BIOCON
LIMITED

REPORT TITLE PAGE 5

 COMPETITIVE ANALYSIS

REPORT TITLE PAGE 6

 CONCLUSION

WHERE DID IT FALL SHORT:

Though the company has pulled up the value chain up in the competition market
but what I believe is that the sector requires a streamline regulatory frame work
support to enhance the commercialization of value products and Biocon fell
short in this framework. Biotechnology is not considered as a priority sector by
the government of India. And it has to rest upon the research and development
only. The sector needs continuous creativity and innovation. To keep this it
requires extensive research work done. Research execution demands expensive
equipment to be imported. Government support is needed for this purpose.
There are some major drawbacks of the Biotechnology Industry which is
impacting Biocon negatively.

ADMIRABLE ABOUT ENTREPRENEUR’S ACTION:

Biocon is a journey from failure to failure and succeeding in the end. Some key
features that admire me about the entrepreneur are her ability to take risks,
challenge the status quo, and never giving up attitude. It is being said that
entrepreneurs are risk takers because they believe that they can transform
anything. But taking risk is an act of intelligence and it needs to manage risks well
as well as mitigate it. And she has done it very efficiently. The other thing that I
like about the entrepreneur is her steps of effective innovation strategies. Biotech
is chocked with lots of regulations and there are huge risks and failure rates but
she has managed it very strategically.

REPORT TITLE PAGE 7